$53.27
0.74% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock price

$53.27
-4.04 7.05% 1M
+3.24 6.48% 6M
+3.54 7.12% YTD
+6.94 14.98% 1Y
+1.97 3.84% 3Y
+7.63 16.72% 5Y
+7.49 16.36% 10Y
Nasdaq, Closing price Fri, Nov 01 2024
+0.39 0.74%
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Key metrics

Market capitalization $133.56b
Enterprise Value $152.06b
P/E (TTM) P/E ratio 29.22
EV/FCF (TTM) EV/FCF 25.81
EV/Sales (TTM) EV/Sales 3.19
P/S ratio (TTM) P/S ratio 2.80
P/B ratio (TTM) P/B ratio 1.71
Dividend yield 3.82%
Last dividend (FY24) $2.04
Revenue growth (TTM) Revenue growth 5.18%
Revenue (TTM) Revenue $47.68b
EBIT (operating result TTM) EBIT $10.14b
Free Cash Flow (TTM) Free Cash Flow $5.89b
EPS (TTM) EPS $1.82
P/E forward 17.82
P/S forward 2.64
EV/Sales forward 3.01
Short interest 0.36%
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Sanofi Sponsored ADR forecast:

16x Buy
76%
3x Hold
14%
2x Sell
10%

Analyst Opinions

21 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
76%
Hold
14%
Sell
10%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
47,675 47,675
5% 5%
100%
- Direct Costs 18,371 18,371
9% 9%
39%
29,304 29,304
3% 3%
61%
- Selling and Administrative Expenses 6,830 6,830
10% 10%
14%
- Research and Development Expense 7,523 7,523
7% 7%
16%
14,951 14,951
8% 8%
31%
- Depreciation and Amortization 4,815 4,815
32% 32%
10%
EBIT (Operating Income) EBIT 10,136 10,136
1% 1%
21%
Net Profit 4,558 4,558
49% 49%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Negative
Forbes
4 days ago
On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.
Neutral
Business Wire
6 days ago
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivota...
Positive
The Motley Fool
9 days ago
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 87,994
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today